Johnson & Johnson
JNJ
$160.26
Share price
-0.15%
Change (1 day)
-3.28%
Change (1 year)
Categories
Johnson & Johnson is a global American pharmaceutical and consumer goods company with headquarters in New Brunswick, New Jersey. The company is listed in the Dow Jones Industrial Average.
Johnson & Johnson (JNJ) - Total liabilities
Total liabilities on the balance sheet as of March 2023 : $125.10 B
According to Johnson & Johnson's latest financial reports the company's total liabilities are $125.10 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Johnson & Johnson - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $110.57 B | 2.39% |
| 2021-12-31 | $107.99 B | -3.24% |
| 2020-12-31 | $111.61 B | 13.6% |
| 2019-12-31 | $98.25 B | 5.42% |
| 2018-12-31 | $93.20 B | -4.06% |
| 2017-12-31 | $97.14 B | 37.23% |
| 2016-12-31 | $70.79 B | 13.7% |
| 2015-12-31 | $62.26 B | 1.46% |
| 2014-12-31 | $61.36 B | 4.67% |
| 2013-12-31 | $58.63 B | 3.73% |
| 2012-12-31 | $56.52 B | -0.08% |
| 2011-12-31 | $56.56 B | 22.09% |
| 2010-12-31 | $46.32 B | 5.07% |
| 2009-12-31 | $44.09 B | 3.99% |
| 2008-12-31 | $42.40 B | 12.66% |
| 2007-12-31 | $37.63 B | 20.48% |
| 2006-12-31 | $31.23 B | 55% |
| 2005-12-31 | $20.15 B | -6.28% |
| 2004-12-31 | $21.50 B | 0.51% |
| 2003-12-31 | $21.39 B | 19.79% |
| 2002-12-31 | $17.85 B | 25.28% |
| 2001-12-31 | $14.25 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $59.04 B | -52.80% | 🇨🇭 Switzerland |
 Pfizer PFE | $94.38 B | -24.56% | 🇺🇸 USA |
 Abbott Laboratories ABT | $36.56 B | -70.77% | 🇺🇸 USA |
 Medtronic MDT | $39.28 B | -68.60% | 🇮🇪 Ireland |
 Eli Lilly LLY | $43.66 B | -65.10% | 🇺🇸 USA |
 Sanofi SNY | $56.95 B | -54.47% | 🇫🇷 France |
 Gilead Sciences GILD | $41.24 B | -67.03% | 🇺🇸 USA |
 Stryker Corporation SYK | $20.04 B | -83.97% | 🇺🇸 USA |
 Merck MRK | $60.89 B | -51.33% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $59.66 B | -52.30% | 🇬🇧 UK |